The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...
An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...
43 Targeting them with CAR-T cells can enhance the immune response against CRC. CYAD-101, developed by Celyad Oncology, is an allogeneic CAR-T cell therapy derived from healthy donors, offering a ...
Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round to progress CAR-T cell therapy pipeline.
A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...
Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases. An investigator-initiated trial is ongoing in ...